HAYWARD, Calif., Nov. 1, 2012 /PRNewswire/ -- Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the third quarter ended September 30, 2012. Revenue for the third quarter was $35.0 million, an increase of $7.6 million, or 28%, as compared to the third quarter of 2011. Revenue from Liposonix, the Company’s non-invasive fat reduction system, was $7.0 million, which was generated from shipments of 81 systems and associated consumables. Total product revenue from treatment tips and consumables for the quarter was $16.9 million, representing 48% of total revenue. Revenue from North America and international markets rose year-over-year by 27% and 28%, respectively, and was driven by growth in Liposonix, Thermage, Fraxel, and Clear + Brilliant brands.
